French biotechnology company Valneva SE (EPA:VLA) has reported positive Phase III results for its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001, Reuters news agency reported on Monday.
According to the company, its latest trial conducted on 4,012 participants aged 18 and older across 26 trial sites in Britain, showed the vaccine prompted a stronger immune response and fewer side-effects than AstraZeneca's (LON:AZN) shot.
Reportedly, Valneva is among a handful of vaccine developers testing their vaccines against one already approved by a regulator, rather than giving volunteers a placebo as shots become more available.
Valneva's Chief Executive, Thomas Lingelbach, was quoted as saying: "These results confirm the advantages often associated with inactivated whole virus vaccines," adding that the company believed it would make an important contribution to the fight against COVID-19.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma